Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome - Related Studies

Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome

This study has been terminated.

Study NCT00092287. Last updated on February 25, 2008. Information provided by Ipsen

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Malignant Carcinoid Syndrome

2	Additional conditions recognized in this trial
		Carcinoid Tumor
		Serotonin Syndrome
		Syndrome

3	More general conditions related to this trial
		Adenocarcinoma
		Carcinoma
		Disease
		Disorders of Environmental Origin
		Drug Toxicity
		Neoplasms
		Neoplasms by Histologic Type
		Neoplasms, Germ Cell and Embryonal
		Neoplasms, Glandular and Epithelial
		Neoplasms, Nerve Tissue
		Neuroectodermal Tumors
		Neuroendocrine Tumors
		Pathologic Processes
		Poisoning

4	Additional drug interventions recognized in this trial
		Angiopeptin
		Lanreotide
		Octreotide
		Somatostatin

5	More general drug interventions related to this trial
		Antineoplastic Agents
		Antineoplastic Agents, Hormonal
		Cardiovascular Agents
		Gastrointestinal Agents
		Hormones
		Hormones, Hormone Substitutes, and Hormone Antagonists
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses

6	Sponsors listed in this trial
		Ipsen